Pharmaceutical Contract Manufacturing And Research Services Market To Reach $472.1 Billion By 2033

Pharmaceutical Contract Manufacturing And Research Services Market Growth & Trends

The global pharmaceutical contract manufacturing and research services market size is expected to reach USD 472.1 billion by 2033, registering a CAGR of 6.5% from 2026 to 2033, according to a new report by Grand View Research, Inc. Pharmaceutical companies are increasingly leveraging CMOs and CDMOs to avoid substantial capital investments in infrastructure and navigate complex regulatory landscapes. This strategic move allows them to concentrate resources on core competencies like drug discovery and commercialization. The economies of scale achieved by specialized contract organizations further contribute to reduced production costs.

The escalating complexity of drug development, particularly in biologics, biosimilars, HPAPIs, and personalized medicine, necessitates the advanced capabilities and expertise readily available within contract service providers. These organizations often possess cutting-edge technologies such as continuous manufacturing and sophisticated handling systems, which prove vital for efficient and compliant production.

Global health trends, including the rising prevalence of chronic diseases and the demand for affordable generics and biosimilars following patent expirations, are also key growth drivers. The stringent and evolving regulatory environment, coupled with the imperative for faster market entry, incentivizes pharmaceutical companies to utilize the established expertise of CMOs and CDMOs. The strategic geographic shifts towards cost-competitive regions like Asia-Pacific and the emergence of integrated CRO-CDMO models offering comprehensive solutions underscore the dynamic growth of this market.

 Request a free sample copy or view report summary: Pharmaceutical Contract Manufacturing And Research Services Market Report

Pharmaceutical Contract Manufacturing And Research Services Market Report Highlights

• Based on service, the manufacturing segment led the pharmaceutical contract manufacturing and research services market with the largest revenue share of 65.8% in 2025.

• The research segment is projected to grow at the fastest CAGR during the forecast period. The segment's growth is driven by the increasing outsourcing of drug discovery, target identification, preclinical studies, bioanalytical testing, clinical trial support, and regulatory consulting by pharmaceutical and biotechnology companies.

• Asia Pacific dominated the pharmaceutical contract manufacturing and research services market with the largest revenue share of 42.3% in 2025.

Pharmaceutical Contract Manufacturing And Research Services Market Segmentation

Grand View Research has segmented global pharmaceutical contract manufacturing and research services market report based on service and region:

Pharmaceutical Contract Manufacturing And Research Services Service Outlook (Revenue, USD Million, 2021 - 2033)

• Manufacturing

  • API/Bulk Drugs

  • Advanced Drug Delivery Formulations

  • Packaging

  • Finished Dose Formulations

    • Solid

    • Liquid

    • Semi-solid Formulations

• Research

  • Oncology

  • Vaccines

  • Inflammation & Immunology

  • Cardiology

  • Neuroscience

  • Others

Pharmaceutical Contract Manufacturing And Research Services Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • UAE

  • Saudi Arabia

  • Kuwait

  • Qatar

  • Oman

List of Key Players of Pharmaceutical Contract Manufacturing And Research Services Market

• Catalent, Inc (Novo Holdings A/S)

• PPD (Thermo Fisher Scientific Inc.)

• AbbVie Inc.

• Advent International, L.P.

• Grifols

• Dalton Pharma Services

• Boehringer Ingelheim International GmbH

• Lonza